[go: up one dir, main page]

AR085662A1 - Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia - Google Patents

Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia

Info

Publication number
AR085662A1
AR085662A1 ARP120100799A ARP120100799A AR085662A1 AR 085662 A1 AR085662 A1 AR 085662A1 AR P120100799 A ARP120100799 A AR P120100799A AR P120100799 A ARP120100799 A AR P120100799A AR 085662 A1 AR085662 A1 AR 085662A1
Authority
AR
Argentina
Prior art keywords
hyperuricemia
compositions
methods
disorders associated
metabolic disorders
Prior art date
Application number
ARP120100799A
Other languages
English (en)
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of AR085662A1 publication Critical patent/AR085662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y composiciones para el tratamiento y/o prevención de la hiperuricemia o trastornos metabólicos asociados a la hiperuricemia, que comprenden administrar a un paciente que lo necesita, una cantidad terapéuticamente efectiva de diacereína, reína, o una sal farmacéuticamente aceptable, un análogo, un profármaco o un metabolito activo de la misma.Reivindicación 6: El uso de acuerdo con la reivindicación 1, en el cual dicho medicamento comprende además por lo menos un agente terapéutico adicional seleccionado del grupo que consiste en agentes antiinflamatorios y agentes reductores de urato. Reivindicación 13: El uso de acuerdo con la reivindicación 10, en el cual dicho agente antiinflamatorio es seleccionado del grupo que consiste en fármacos antiinflamatorios no esteroides (AlNEs), corticosteroides, colchicinas y una combinación de los mismos.
ARP120100799A 2011-03-11 2012-03-12 Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia AR085662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11

Publications (1)

Publication Number Publication Date
AR085662A1 true AR085662A1 (es) 2013-10-16

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100799A AR085662A1 (es) 2011-03-11 2012-03-12 Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia

Country Status (16)

Country Link
US (1) US8865689B2 (es)
EP (1) EP2683372B1 (es)
JP (1) JP6012639B2 (es)
KR (1) KR101567885B1 (es)
CN (1) CN103429236B (es)
AR (1) AR085662A1 (es)
AU (1) AU2012229443B2 (es)
BR (1) BR112013022332A2 (es)
CA (1) CA2829101C (es)
ES (1) ES2634562T3 (es)
IL (1) IL228030B (es)
MX (1) MX350666B (es)
PT (1) PT2683372T (es)
RU (1) RU2603050C2 (es)
TW (1) TWI505827B (es)
WO (1) WO2012125359A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794566C (en) * 2010-04-08 2018-06-12 Twi Biotechnology, Inc. Methods of using diacerein as an adjunctive therapy for diabetes
MX350666B (es) 2011-03-11 2017-09-12 Twi Biotechnology Inc Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
RU2690372C2 (ru) * 2015-04-20 2019-06-03 Тви Биотекнолоджи, Инк. Лекарственные средства, содержащие диацереин, и способы снижения уровней мочевой кислоты в крови с его использованием
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
WO2017004319A1 (en) 2015-07-01 2017-01-05 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
BR112018003212A2 (pt) * 2015-08-17 2018-09-25 Twi Biotechnology Inc diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
RU2450824C2 (ru) * 2006-10-20 2012-05-20 Ридженерон Фармасьютикалз, Инк. Применение антагонистов il-1 для лечения подагры
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
PL2224914T3 (pl) * 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
WO2010003092A1 (en) * 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
MX350666B (es) 2011-03-11 2017-09-12 Twi Biotechnology Inc Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.

Also Published As

Publication number Publication date
KR20140019795A (ko) 2014-02-17
US20120232044A1 (en) 2012-09-13
JP2014507476A (ja) 2014-03-27
TWI505827B (zh) 2015-11-01
PT2683372T (pt) 2017-10-25
MX2013010384A (es) 2013-10-07
IL228030A0 (en) 2013-09-30
ES2634562T3 (es) 2017-09-28
IL228030B (en) 2018-01-31
TW201249432A (en) 2012-12-16
JP6012639B2 (ja) 2016-10-25
CN103429236B (zh) 2016-09-21
KR101567885B1 (ko) 2015-11-10
CA2829101C (en) 2019-08-20
NZ614486A (en) 2014-11-28
CN103429236A (zh) 2013-12-04
AU2012229443A1 (en) 2013-09-12
BR112013022332A2 (pt) 2017-05-30
WO2012125359A1 (en) 2012-09-20
RU2013145498A (ru) 2015-04-20
US8865689B2 (en) 2014-10-21
EP2683372A1 (en) 2014-01-15
MX350666B (es) 2017-09-12
CA2829101A1 (en) 2012-09-20
EP2683372A4 (en) 2014-08-06
AU2012229443B2 (en) 2017-03-02
EP2683372B1 (en) 2017-07-12
RU2603050C2 (ru) 2016-11-20

Similar Documents

Publication Publication Date Title
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
MX2019012884A (es) Terapia de combinacion.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
RU2013121788A (ru) Ингибиторы репликации вич
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112015012497A2 (pt) combinações farmacêuticas
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
AR108793A1 (es) Composiciones que comprenden timolol y un agente antiinflamatorio
AR108792A1 (es) Composiciones que comprenden timolol
AR068382A1 (es) Composicion farmaceutica compuesta por la combinacion de un antiinflamatorio esteroideo y un relajante muscular indicada para el conrol y tratamiento de enfermedades inflamatorias musculoesqueleticas que se acompanan de contractura muscular
MX2024011932A (es) Combinaciones farmaceuticas y metodos de uso del compuesto de amino-pirrolopirimidinona

Legal Events

Date Code Title Description
FB Suspension of granting procedure